## Summary Report of Edwards Lifesciences Earnings Conference Call

### Key Financial Highlights - Q4 2020 and Full Year 2020
- **Q4 2020 Sales:** $1.2 billion, consistent with the previous year despite ongoing pandemic impacts.
- **Full Year 2020 Sales:** Increased by 1% to $4.4 billion.
- **Adjusted Earnings Per Share (EPS) Q4 2020:** Grew by 2% to $0.50.
- **Full Year 2020 Adjusted EPS:** Remained flat at $1.86.
- **Adjusted Free Cash Flow for 2020:** Exceeded $700 million.
- **Total Global TAVR (Transcatheter Aortic Valve Replacement) Sales for 2020:** $2.9 billion, up 4% on an underlying basis.

### Strategic Highlights and Business Updates
- Amidst COVID-19 disruptions, Edwards Lifesciences maintained its market leadership in TAVR with stable prices and growing adoption.
- The company introduced the KONECT aortic valved conduit and reported strong global utilization of the Inspiris aortic surgical valve.
- Significant progress in the Critical Care portfolio, with high demand for core pressure monitoring products.
- Expansion into Transcatheter Mitral and Tricuspid Therapies (TMTT) with over 3,000 patients treated, positive clinical results from PASCAL Ace.
- Surgical Structural Heart experienced a decline, but ongoing innovations and new launches (KONECT and Inspiris valves) are expected to drive recovery.

### Financial Guidance for 2021
- **2021 Sales Forecast:** $4.9 billion to $5.3 billion, indicating mid-teens underlying growth.
- **TAVR Expected Sales:** Between $3.2 billion and $3.6 billion.
- **TMTT Expected Sales:** Approx. $80 million; projected to double from previous levels.
- **Surgical Structural Heart Forecast:** $800 million to $900 million.
- **Critical Care Forecast:** $725 million to $800 million.
- **Adjusted EPS:** Expected to be between $2.00 and $2.20.
- **Q1 2021 Sales Projection:** Between $1.1 billion and $1.2 billion with adjusted EPS between $0.43 and $0.50.

### Investment Considerations
Given the resilient performance in 2020 and strong guidance for 2021, an 'overweight' investment stance is recommended. Edwards Lifesciences demonstrated robust capability to navigate through pandemic challenges with effective strategic management and innovation. The projected growth rates, especially in TAVR and TMTT, alongside global expansion and strong pipeline developments, solidify the potential for sustained long-term growth. Investors should note the ongoing recovery in surgical procedures and the potential uptick in elective surgeries as pandemic conditions abate, supported by vaccination rollouts, which can further catalyze revenue growth across different business segments. Thus, Edwards Lifesciences represents a solid investment opportunity with an optimistic growth trajectory.

### Conclusion
Edwards Lifesciences is poised to continue its growth with strategic focus on innovation, geographic and product line expansion, and sustained investment in R&D and patient-centric solutions. As the global healthcare environment recovers and adapitialpa improvements increase, the company is well-positioned to capitalize on its leading technologies and robust pipeline, supporting long-term value creation for stakeholders.